To the Medicine by Design community,
I am delighted to let you know that Allison Brown is joining Medicine by Design as our new Director, Strategy and Translation, effectively replacing Ariana Bradford who has taken a leadership role at the Munk School of Global Affairs & Public Policy. Allison brings domain knowledge and expertise in partnerships and translation that will be important for the next phase of Medicine by Design.
The administrative structure at Medicine by Design has been reconfigured to enable this emphasis on translation. I want to take this opportunity to thank Ann Perry who has been Acting Director, Strategy and Operations since the beginning of January; her help has been and will continue to be essential in this transition and beyond. Ann will continue as Manager of Communications and Operations, reporting to Allison.
Allison brings to this position more than 14 years of experience at the intersection of research, commercialization and business development. For the past three years, she has served as Director, Corporate and Foundation Partnerships, at the Faculty of Applied Science & Engineering at the University of Toronto, where she has forged partnerships in the public and private sectors to tackle new research challenges. She has also worked in senior roles at CCRM and in industry. Allison holds PhD and BASc degrees in Chemical Engineering and Applied Chemistry from U of T.
Leading the Medicine by Design staff team, Allison will play a key role in advancing the initiative’s strategic and scientific priorities and accelerating the translation of Medicine by Design-funded research.
Allison’s first day at Medicine by Design will be April 4. Please join me in welcoming her to our community.
Michael Sefton, OC
Executive Director, Medicine by Design
Institute of Biomaterials and Biomedical Engineering,
Michael E. Charles Professor, Department of Chemical Engineering and Applied Chemistry
University of Toronto